July/August #189 : Cure: HDAC Inhibitors May Fight HIV Reservoir - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Magnetic Attraction

A Shred of Understanding

Hold Your Horses

From the Editor

Accentuate the Positive

Feedback

Letters-July/August 2013

The POZ Q+A

Pride and Policy

POZ Planet

Say What?—Alicia Keys

Greetings from Ptown

PACHA Covers Trans Issues

Making Headlines

Latest Developments

Not Another Gay Sex Disease

Future Lovers

On a Roll

Voices

Yours in the Struggle

Care and Treatment

The Quest to Cure Another Baby

Viral Suppression Without Drugs?

The Genetic Fusion Inhibitor

New Retention Guidelines Urge Partnerships

Mapping Viral and Immune Coevolution

Research Notes

Prevention: PrEP May Be Cost-Effective

Treatement: Can Bees Sting Away HIV?

Cure: HDAC Inhibitors May Fight HIV Reservoir

Concerns: Hep C Transmission Among Gay Men

POZ Survey Says

Accentuate the Negative

POZ Heroes

Chemical Crusader

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

July / August 2013

Cure: HDAC Inhibitors May Fight HIV Reservoir

by Benjamin Ryan

Scientists at Merck Research Laboratories are looking into a potential way to bring resting HIV out of latency—a necessary step in ultimately eradicating the virus from the body. A Merck-sponsored team hopes to hone strategies that may lead to a functional cure, allowing people with HIV to stop ARVs without experiencing a viral rebound. Merck scientists are investigating small molecules that may be able to enhance the amount of viral expression seen in recent studies of histone deacetylase (HDAC) inhibitors. These are drugs used for both psychiatric and neurologic purposes as mood stabilizers and anti-epileptics. More recently, the drugs have been studied as anti-cancer agents and have also shown promise as a potential component of such an HIV cure strategy, but which on their own seem insufficient to chip away at the viral reservoir.

Search: Merck Research Laboratories, deacetylase, inhibitors, HDAC

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    Sin_Grinder
    Reno
    Nevada


    Fred9774
    Brooklyn
    New York

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.